Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Arch Biochem Biophys ; 680: 108242, 2020 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-31899146

RESUMO

Inflammatory bowel disease (IBD) is a chronic inflammatory condition with high incidence. Syringin exhibits multiple pharmacological properties, including anti-inflammatory effects. However, the effect of syringin on inflammation of IBD is still unclear. Here, the dextran sulfate sodium (DSS)-induced colitis model was established in vivo. Rat intestinal epithelium IEC6 cells were treated with lipopolysaccharide (LPS) in vitro. Syringin inhibited DSS or LPS-induced overproduction of proinflammatory cytokines (IL-1ß, IL-6, TNF-α) and proinflammatory substances (iNOS, COX-2). Moreover, syringin inactivated the proinflammatory NF-κB p65 pathway by decreasing IκBα phosphorylation at Ser 32. The activation of antioxidant Nrf2 signaling pathway was promoted by syringin. Additionally, LPS-induced inflammation in IEC6 cells was also suppressed by NF-κB inhibitor PDTC and Nrf2 activator RTA408. The anti-inflammatory effects of syringin were comparable to these two reagents. Taken together, our results suggest that syringin shows protective effects on intestinal inflammation through inhibiting NF-κB, while activating Nrf2 signaling pathway in colitis.


Assuntos
Anti-Inflamatórios/uso terapêutico , Colite/tratamento farmacológico , Glucosídeos/uso terapêutico , Inflamação/tratamento farmacológico , Fenilpropionatos/uso terapêutico , Animais , Anti-Inflamatórios/farmacologia , Linhagem Celular , Colite/imunologia , Citocinas/imunologia , Glucosídeos/farmacologia , Inflamação/imunologia , Doenças Inflamatórias Intestinais/tratamento farmacológico , Doenças Inflamatórias Intestinais/imunologia , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/imunologia , Lipopolissacarídeos/imunologia , Camundongos Endogâmicos BALB C , Fator 2 Relacionado a NF-E2/imunologia , NF-kappa B/imunologia , Fenilpropionatos/farmacologia , Ratos
2.
Opt Express ; 25(13): 15299-15312, 2017 Jun 26.
Artigo em Inglês | MEDLINE | ID: mdl-28788957

RESUMO

Based on our previous study and designed experimental AO system with a 97-element continuous surface deformable mirror, we conduct the performance analysis of a coherent free space optical communication (FSOC) system for mixing efficiency (ME), bit error rate (BER) and outage probability under different Greenwood frequency and atmospheric coherent length. The results show that the influence of the atmospheric temporal characteristics on the performance is slightly stronger than that of the spatial characteristics when the receiving aperture and the number of sub-apertures are given. This analysis result provides a reference for the design of the coherent FSOC system.

3.
Curr Microbiol ; 74(10): 1169-1177, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28710513

RESUMO

It is well documented that the microbial interactions and biodiversity play an important role in health and disease in mammalian species. There is a rare study about gut microbiota of Mustelidae family. In this study, 40 male and female minks from Northeast China were divided into three groups and fed until they reached maturity. The V3 region of 16S rRNA genes was amplified and sequenced using NGS. There were 526 OTUs principally concentrated among five bacterial phyla. Two points about mink's body weight gaining were observed: (1) the weight of male individuals increased more rapidly than female individuals; (2) the weight of individuals whose feed was supplemented with Chinese herb additives increased more rapidly than individuals without giving food additives. The differences of microorganism abundance were shown in two points: (1) two genera which had ≥2-fold change difference were found between male and female minks. (2) Ten genera which had a ≥2-fold change difference were found among minks with and without Chinese herb additive. Findings from this study provide new and fundamental knowledge on the gut microbiota composition of minks farmed in Northeast China, which can contribute to the general well-being of minks worldwide.


Assuntos
Microbioma Gastrointestinal , Metagenoma , Metagenômica , Vison/microbiologia , Animais , Biodiversidade , Biologia Computacional , Evolução Molecular , Feminino , Aditivos Alimentares , Sequenciamento de Nucleotídeos em Larga Escala , Masculino , Metagenômica/métodos , Filogenia , RNA Ribossômico 16S/genética , Fatores Sexuais
4.
Eur J Med Chem ; 256: 115444, 2023 Aug 05.
Artigo em Inglês | MEDLINE | ID: mdl-37178483

RESUMO

Proteolysis-targeting chimeras (PROTACs) as an emerging drug discovery modality has been extensively concerned in recent years. Over 20 years development, accumulated studies have demonstrated that PROTACs show unique advantages over traditional therapy in operable target scope, efficacy, and overcoming drug resistance. However, only limited E3 ligases, the essential elements of PROTACs, have been harnessed for PROTACs design. The optimization of novel ligands for well-established E3 ligases and the employment of additional E3 ligases remain urgent challenges for investigators. Here, we systematically summarize the current status of E3 ligases and corresponding ligands for PROTACs design with a focus on their discovery history, design principles, application benefits, and potential defects. Meanwhile, the prospects and future directions for this field are briefly discussed.


Assuntos
Descoberta de Drogas , Ubiquitina-Proteína Ligases , Proteólise , Ligantes , Ubiquitina-Proteína Ligases/metabolismo
5.
J Med Chem ; 66(11): 7421-7437, 2023 06 08.
Artigo em Inglês | MEDLINE | ID: mdl-37212861

RESUMO

Triple-negative breast cancer (TNBC) is a leading malignancy among women that currently lack effective targeted therapeutic agents, and the limitations of treatment have prompted the emergence of new strategies. Methuosis is a novel vacuole-presenting cell death modality that promotes tumor cell death. Hence, a series of pyrimidinediamine derivatives were designed and synthesized through evaluation of their abilities that inhibit proliferation as well as induce methuosis against TNBC cells. Among them, JH530 showed excellent anti-proliferative activities and vacuolization capacity in TNBC. The mechanism research indicated that JH530 caused cell death through inducing methuosis of cancer cells. Furthermore, JH530 inhibited tumor growth remarkably in the HCC1806 xenograft model without an apparent decrease in body weight. Overall, JH530 is a methuosis inducer that displayed remarkable suppression of TNBC growth in vitro and in vivo, which provides a basis for the future progress of more small molecules for TNBC treatment.


Assuntos
Antineoplásicos , Neoplasias de Mama Triplo Negativas , Humanos , Feminino , Apoptose , Neoplasias de Mama Triplo Negativas/patologia , Ensaios Antitumorais Modelo de Xenoenxerto , Linhagem Celular Tumoral , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Proliferação de Células
6.
J Med Chem ; 66(24): 16917-16938, 2023 12 28.
Artigo em Inglês | MEDLINE | ID: mdl-38054798

RESUMO

Myoferlin (MYOF) mediates the growth and metastasis of various cancers as an emerging therapeutic target by regulating exocytosis and endocytosis. However, the previously reported MYOF inhibitor, 6y, failed to be a favorable candidate agent due to its poor physicochemical properties, such as water solubility, in preclinical studies. Naturally, a novel range of MYOF inhibitors was synthesized and optimized based on the lead compound 6y. The optimal compound HJ445A potently repressed the proliferation of gastric cancer cells with IC50 values of 0.16 and 0.14 µM in MGC803 and MKN45, respectively. Moreover, HJ445A bound to the MYOF-C2D domain with a KD of 0.17 µM, and HJ445A prevented the migration of gastric cancer cells by reversing the epithelial-mesenchymal transition (EMT) process and inhibited the colony formation of the MKN45 cells in a concentration-dependent manner. Notably, the water solubility of HJ445A was significantly improved compared to 6y, with about 170-fold enhancement. Additionally, HJ445A also demonstrated superior antitumor efficacy in vivo.


Assuntos
Neoplasias Gástricas , Humanos , Neoplasias Gástricas/tratamento farmacológico , Solubilidade , Água/metabolismo , Linhagem Celular Tumoral , Proliferação de Células , Movimento Celular , Proteínas de Ligação ao Cálcio , Proteínas de Membrana/metabolismo , Proteínas Musculares/metabolismo
7.
Zootaxa ; 5213(5): 569-577, 2022 Nov 29.
Artigo em Inglês | MEDLINE | ID: mdl-37044921

RESUMO

A new gomphid species, Ophiogomphus tibeticus sp. nov., from Zoige alpine Wetland, Sichuan is described and illustrated. Assignment to the genus Ophiogomphus Selys, 1854 is based on both morphological and molecular analyses. This new species differs from other known Ophiogomphus mainly in the shape of the caudal appendages.


Assuntos
Dipterocarpaceae , Odonatos , Animais , China
8.
J Med Chem ; 65(23): 15559-15583, 2022 12 08.
Artigo em Inglês | MEDLINE | ID: mdl-36441945

RESUMO

B-cell lymphoma 6 (BCL6) is a transcriptional repressor that regulates the differentiation of B lymphocytes and mediates the formation of germinal centers (GCs) by recruiting corepressors through the BTB domain of BCL6. Physiological processes regulated by BCL6 involve cell activation, differentiation, DNA damage, and apoptosis. BCL6 is highly expressed when the gene is mutated, leading to the malignant proliferation of cells and drives tumorigenesis. BCL6 overexpression is closely correlated with tumorigenesis in diffuse large B-cell lymphoma (DLBCL) and other lymphomas, and BCL6 inhibitors can effectively inhibit some lymphomas and overcome resistance. Therefore, targeting BCL6 might be a promising therapeutic strategy for treating lymphomas. Herein, we comprehensively review the latest development of BCL6 inhibitors in diffuse large B-cell lymphoma and discuss the overview of the pharmacophores of BCL6 inhibitors and their efficacies in vitro and in vivo. Additionally, the current advances in BCL6 degraders are provided.


Assuntos
Linfoma Difuso de Grandes Células B , Humanos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Desenvolvimento de Medicamentos
9.
Future Med Chem ; 14(20): 1425-1440, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-36165130

RESUMO

Aim: The first inhibitor targeting myoferlin (MYOF), WJ460, bears poor metabolic stability and water solubility. Therefore, this study aimed to improve the drug-like properties of WJ460. Materials & methods: The authors synthesized an array of 1,5-diaryl-1,2,4-triazole analogs and appraised the binding activities with MYOF and their antiproliferative and antimigratory activities against pancreatic cancer cells. Results: Molecular docking and surface plasmon resonance results showed that E4 was directly bound to the MYOF-C2D domain. E4 effectively inhibited the proliferation and migration of pancreatic cancer cells in vitro. An in silico study suggested that the water solubility of E4 was improved by about 22-times than that of WJ460. Conclusion: The findings suggested that the druglike ability of E4 was significantly improved.


Assuntos
Antineoplásicos , Neoplasias Pancreáticas , Humanos , Proteínas de Ligação ao Cálcio/metabolismo , Proteínas Musculares/metabolismo , Proteínas de Membrana/metabolismo , Simulação de Acoplamento Molecular , Neoplasias Pancreáticas/tratamento farmacológico , Água , Proliferação de Células , Linhagem Celular Tumoral , Antineoplásicos/farmacologia , Relação Estrutura-Atividade , Neoplasias Pancreáticas
10.
J Med Chem ; 65(19): 12650-12674, 2022 10 13.
Artigo em Inglês | MEDLINE | ID: mdl-36103247

RESUMO

Accumulating evidence has documented that STAT3 phosphorylation at Tyr705 and Ser727 jointly promotes the initiation and progression of gastric cancer. However, most reported STAT3 inhibitors have mainly focused on suppressing STAT3 phosphorylation at Tyr705 while ignoring the tumorigenic effects of phosphorylation at Ser727. Herein, we described the design, synthesis, and structure-activity relationship studies on a series of triaromatic heterocyclic derivatives as potent dual phosphorylation STAT3 inhibitors. These efforts led to the discovery of the best compound 3h (HP590) among the investigated ones, a novel, highly potent, and orally bioavailable STAT3 inhibitor possessing lower nanomolar inhibitory activity toward p-Tyr705 and p-Ser727. Target validation revealed that HP590 selectively targets STAT3 to remarkably inhibit its canonical and noncanonical activation and corresponding biological functions, thereby resulting in the growth inhibition of gastric cancer in vitro and in vivo, highlighting the therapeutic potential of dual phosphorylation STAT3 inhibitors for gastric cancer.


Assuntos
Neoplasias Gástricas , Linhagem Celular Tumoral , Humanos , Fosforilação , Fator de Transcrição STAT3/metabolismo , Neoplasias Gástricas/tratamento farmacológico
11.
Clin Transl Med ; 11(2): e289, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33634965

RESUMO

As a pivotal vesicular trafficking protein, Myoferlin (MYOF) has become an attractive target for cancer therapy. However, the roles of MYOF in colorectal cancer invasion remain enigmatic, and MYOF-targeted therapy in this malignancy has not been explored. In the present study, we provided the first functional evidence that MYOF promoted the cell invasion of colorectal cancer. Furthermore, we identified a novel small molecule inhibitor of MYOF (named YQ456) that showed high binding affinity to MYOF (KD  = 37 nM) and excellent anti-invasion capability (IC50  = 110 nM). YQ456 was reported for the first time to interfere with the interactions between MYOF and Ras-associated binding (Rab) proteins at low nanomolar levels. This interference disrupted several vesicle trafficking processes, including lysosomal degradation, exosome secretion, and mitochondrial dynamics. Further, YQ456 exhibited excellent inhibitory effects on the growth and invasiveness of colorectal cancer. As the first attempt, the anticancer efficacy of YQ456 in the patient-derived xenograft (PDX) mouse model indicated that targeting MYOF may serve as a novel and practical therapeutic approach for colorectal cancer.


Assuntos
Antineoplásicos/farmacologia , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/genética , Proteínas de Membrana/antagonistas & inibidores , Proteínas de Membrana/genética , Proteínas Musculares/antagonistas & inibidores , Proteínas Musculares/genética , Animais , Neoplasias Colorretais/patologia , Modelos Animais de Doenças , Progressão da Doença , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Invasividade Neoplásica
12.
Mol Phylogenet Evol ; 56(1): 252-8, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20026410

RESUMO

The mysterious Asian hynobiid salamander, Protohynobius puxiongensis, was described based on a single specimen collected in 1965 and never found again since then. Because the specimen had an internasal bone, Pr. puxiongensis was thought to retain a primitive character lost by a common ancestor of all other hynobiid salamanders, and it was thus considered to be not only a new genus, but also a new subfamily. This conclusion bothered herpetologists for decades because it was based on only one specimen and one character without other living specimens being rediscovered. After years of field effort, we rediscovered living individuals of Pr. puxiongensis at its type locality. All characters observed in rediscovered specimens are identical to the original description of the holotype except the internasal bone, implying that the internasal bone observed in the holotype may be just an individual variation. To examine the phylogenetic position of Pr. puxiongensis, we sequenced complete mitochondrial genomes for this species, together with two Pseudohynobius species. By combining 18 published hynobiid mitochondrial genomes and our new sequences, we reconstructed a comprehensive phylogenetic relationship of Hynobiidae at the genus level. Our results indicate that Pr. puxiongensis is deeply nested within the hynobiid phylogeny. It is the sister group of the Pseudohynobius species, and the validity of subfamily Protohynobiinae is not supported.


Assuntos
Evolução Molecular , Genoma Mitocondrial , Filogenia , Urodelos/genética , Animais , Teorema de Bayes , DNA Mitocondrial/genética , Modelos Genéticos , Alinhamento de Sequência , Análise de Sequência de DNA , Urodelos/anatomia & histologia , Urodelos/classificação
13.
Curr Top Med Chem ; 20(17): 1509-1515, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32552653

RESUMO

Myoferlin (MYOF), as a member of the ferlin family, is a type II transmembrane protein with a single transmembrane domain at the carbon terminus. Studies have shown that MYOF is involved in pivotal physiological functions related to numerous cell membranes, such as extracellular secretion, endocytosis cycle, vesicle trafficking, membrane repair, membrane receptor recycling, and secreted protein efflux. Recently, the studies have also revealed that MYOF is overexpressed in a variety of cancers such as colorectal cancer, pancreatic cancer, breast cancer, melanoma, gastric cancer, and non-small-cell lung cancer. High expression of MYOF is associated with the high invasion of tumors and poor clinical prognosis. MYOF medicates the expression, secretion, and distribution of proteins, which were closely related to cancers, as well as the energy utilization of cancer cells, lipid metabolism and other physiological activities by regulating the physiological processes of membrane transport. In this short article, we briefly summarize the latest progress related to MYOF, indicating that small molecule inhibitors targeting the MYOF-C2D domain can selectively inhibit the proliferation and migration of cancer cells, and MYOF may be a promising target for the treatment of malignant tumors.


Assuntos
Antineoplásicos/farmacologia , Proteínas de Ligação ao Cálcio/antagonistas & inibidores , Proteínas de Membrana/antagonistas & inibidores , Proteínas Musculares/antagonistas & inibidores , Neoplasias/tratamento farmacológico , Proteínas de Ligação ao Cálcio/genética , Proteínas de Ligação ao Cálcio/metabolismo , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Humanos , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Estrutura Molecular , Proteínas Musculares/genética , Proteínas Musculares/metabolismo , Neoplasias/metabolismo , Neoplasias/patologia
14.
J Med Chem ; 63(2): 676-695, 2020 01 23.
Artigo em Inglês | MEDLINE | ID: mdl-31895575

RESUMO

The transcriptional repressor B-cell lymphoma 6 (BCL6) is frequently misregulated in diffuse large B-cell lymphoma (DLBCL) and has emerged as an attractive drug target for the treatments of lymphoma. In this article, a series of N-phenyl-4-pyrimidinamine derivatives were designed and synthesized as potent BCL6 inhibitors by optimizing hit compound N4-(3-chloro-4-methoxyphenyl)-N2-isobutyl-5-fluoro-2,4-pyrimidinediamine on the basis of the structure-activity relationship. Among them, compound 14j displayed the most potent activities, which significantly blocked the interaction of BCL6 with its corepressors, reactivated BCL6 target genes in a dose-dependent manner, and had better effects compared with the two positive controls. Further studies indicated that a low dose of 14j could effectively inhibit germinal center formation. More importantly, 14j not only showed potent inhibition of DLBCL cell proliferation in vitro but also strongly suppressed the growth of DLBCL in vivo.


Assuntos
Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Proteínas Proto-Oncogênicas c-bcl-6/antagonistas & inibidores , Pirimidinas/síntese química , Pirimidinas/farmacologia , Animais , Apoptose/efeitos dos fármacos , Proliferação de Células , Relação Dose-Resposta a Droga , Repressão Epigenética/efeitos dos fármacos , Centro Germinativo/efeitos dos fármacos , Células HEK293 , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Modelos Moleculares , Simulação de Acoplamento Molecular , Proteínas Proto-Oncogênicas c-bcl-6/genética , Relação Estrutura-Atividade , Ensaios Antitumorais Modelo de Xenoenxerto
15.
Sci Rep ; 9(1): 13150, 2019 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-31511543

RESUMO

As a continuation of our previous work [Optics Express.25, 15229(2017)] in which we have verified the performance of a coherent free space optical communication (FSOC) system with a 97-element adaptive optics (AO) system, in this paper, we evaluated the performance improvement of the coherent FSOC system using a large-scale high-speed AO system with a 349-element continuous surface deformable mirror. The mixing efficiency (ME) and bit-error-rate (BER) under different Greenwood frequency (GF) were calculated as the performance metric of coherent FSOC system. The performance of FSOC system using such a large-scale AO system was quantitatively verified for the first time. The obtained results showed that the performance was obviously improved when a larger-scale high-speed AO system is employed in coherent FSOC system. This analysis result provides a performance verification for large-scale high-speed AO systems used in FSOC system which is beneficial for coherent FSOC system parameters design.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA